These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31923049)

  • 1. Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
    García-Ropero Á; Vargas-Delgado AP; Santos-Gallego CG; Badimon JJ
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):269-275. PubMed ID: 31923049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation, bleeding, and coronary intervention: current recommendations.
    Farhan S; Mehran R
    Coron Artery Dis; 2017 Dec; 28(8):702-709. PubMed ID: 28938240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Oral Anticoagulants Following Percutaneous Coronary Intervention.
    Abadie BQ; Cannon CP; Cavender MA
    Circ Cardiovasc Interv; 2020 Jul; 13(7):e008465. PubMed ID: 32673510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should all stent patients have prolonged dual antiplatelet therapy?
    Kirtane AJ; King SB
    JACC Cardiovasc Interv; 2015 May; 8(6):873-875. PubMed ID: 25999115
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 11. Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
    Said A; Keeney S; Matka M; Hafeez A; George J; Halalau A
    BMC Cardiovasc Disord; 2020 Jun; 20(1):263. PubMed ID: 32487114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
    Kessler T; Wolf B; Eriksson N; Kofink D; Mahmoodi BK; Rai H; Tragante V; Åkerblom A; Becker RC; Bernlochner I; Bopp R; James S; Katus HA; Mayer K; Munz M; Nordio F; O'Donoghue ML; Sager HB; Sibbing D; Solakov L; Storey RF; Wobst J; Asselbergs FW; Byrne RA; Erdmann J; Koenig W; Laugwitz KL; Ten Berg JM; Wallentin L; Kastrati A; Schunkert H
    Cardiovasc Res; 2019 Aug; 115(10):1512-1518. PubMed ID: 30768153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
    Boden WE; Bhatt DL
    Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.
    Rubboli A; Faxon DP; Juhani Airaksinen KE; Schlitt A; Marín F; Bhatt DL; Lip GY
    Thromb Haemost; 2014 Dec; 112(6):1080-7. PubMed ID: 25298351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy in diabetic patients with coronary artery disease.
    Lemesle G; Bauters A; Bauters C
    Panminerva Med; 2015 Jun; 57(2):87-99. PubMed ID: 25585230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.